Patients who are diagnosed with stage I HR-positive breast cancer typically undergo
to reduce the risk of disease recurrence, explained Reshma Jagsi, MD, DPhil, the Lawrence W. Davis professor and the chair of radiation oncology at the Emory University School of Medicine and a researcher at the Winship Cancer Institute of Emory University.
She added that, in recent studies, patients 65 years and older who opted out of adjuvant radiotherapy had a low risk of disease recurrence, suggesting that older patients may be able to safely skip radiotherapy after breast-conserving surgery.
Advertisement
However, it remained unclear whether younger patients could safely opt out of adjuvant radiotherapy.
Postmenopausal Triumph Over Breast Cancer Challenges
“Although techniques of radiation treatment have improved dramatically, and it is far more efficient and tolerable now than it used to be, patients appreciate having a choice about their treatments,” Jagsi noted.
To determine if omitting radiotherapy would be feasible for younger postmenopausal patients with early-stage breast cancer, Jagsi and colleagues conducted the IDEA clinical trial, which enrolled patients between 50 and 69 years of age who had stage I HR-positive, HER2-negative breast cancer.
The Oncotype DX recurrence score was used to determine each patient’s risk of recurrence based on the genetic profiles of their tumors.
Patients with a low risk of recurrence were eligible to skip radiotherapy after breast-conserving surgery while still receiving standard-of-care adjuvant endocrine therapy for at least five years.
Two hundred patients enrolled in the study were eligible to skip radiotherapy (60 patients 50-59 years old and 140 patients 60-69 years old).
Among 186 evaluable patients, 100% were alive five years after surgery, and 99% (184 patients) were breast cancer-free at this time.
“These findings indicate that younger postmenopausal patients with stage I breast cancer who skip radiotherapy after breast-conserving surgery have a very low risk of disease recurrence within five years,” said Jagsi.
“However, five years is an early time point for this population, and longer-term follow-up of this study and others will be essential to determine whether this option can be safely offered to women in this age group.
“Studies like this one are important for identifying ways to improve the patient experience, both by identifying multiple treatment options to help patients regain a sense of control that a cancer diagnosis can seem to take away, and by ensuring that all patients are informed and empowered to make the decisions that are right for them,” Jagsi said.
Limitations of the study include the short follow-up time and the small sample size.
Reference :
- Omission Of Radiotherapy After Breast-Conserving Surgery For Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
– (https://ascopubs.org/doi/10.1200/JCO.23.02270) - The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)
– (https://clinicaltrials.gov/study/NCT02400190)
Source: Eurekalert
